Recent Findings on Safety Profiles of Cyclodextrins, Cyclodextrin Conjugates, and Polypseudorotaxanes

Cyclodextrins in Pharmaceutics, Cosmetics, and Biomedicine: Current and Future Industrial Applications

Volumn , Issue , 2011, Pages 91-122

  Arima, Hidetoshi ^a   Motoyama, Keiichi ^a   Irie, Tetsumi ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Selective relaxant binding agent (SRBA); Small interfering RNA (siRNA); Transepithelial electrical resistance (TEER)

Indexed keywords

EID: 84884137107     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470926819.ch5     Document Type: Chapter

References (224)

1. Slain, D., Rogers, P.D., Cleary, J.D., Chapman, S.W. (2001). Intravenous itraconazole. Ann. Pharmacother., 35, 720-729.
2. Szejtli, J., Szente, L. (2005). Elimination of bitter, disgusting tastes of drugs and foods by cyclodextrins. Eur. J. Pharm. Biopharm., 61, 115-125.
3. Matsuda, H., Arima, H. (1999). Cyclodextrins in transdermal and rectal delivery. Adv. Drug Deliv. Rev., 36, 81-99.
4. Uekama, K., Otagiri, M. (1987). Cyclodextrins in drug carrier systems. Crit. Rev. Ther. Drug Carrier Syst., 3, 1-40.
5. Thompson, D.O. (1997). Cyclodextrins-enabling excipients: their present and future use in pharmaceuticals. Crit. Rev. Ther. Drug Carrier Syst., 14, 1-104.
6. Brewster, M.E., Loftsson, T. (2007). Cyclodextrins as pharmaceutical solubilizers. Adv. Drug Deliv. Rev., 59, 645-666.
7. Akasaka, H., Endo, T., Nagase, H., Ueda, H., Kobayashi, S. (2000). Complex formation of cyclomaltononaose d-cyclodextrin (d-CD) with macrocyclic compounds. Chem. Pharm. Bull., 48, 1986-1989.
8. Uekama, K. (2004). Design and evaluation of cyclodextrinbased drug formulation. Chem. Pharm. Bull., 52, 900-915.
9. Albers, E., Muller, B.W. (1995). Cyclodextrin derivatives in pharmaceutics. Crit. Rev. Ther. Drug Carrier Syst., 12, 311-337.
10. Uekama, K., Hirayama, F., Irie, T. (1998). Cyclodextrin drug carrier systems. Chem. Rev., 98, 2045-2076.
11. Tavornvipas, S., Hirayama, F., Arima, H., Uekama, K., Ishiguro, T., Oka, M., Hamayasu, K., Hashimoto, H. (2002). 6-O-a-(4-O-a-D-glucuronyl)-D-glucosyl-b-cyclodextrin: solubilizing ability and some cellular effects. Int. J. Pharm., 249, 199-209.
12. Okada, Y., Kubota, Y., Koizumi, K., Hizukuri, S., Ohfuji, T., Ogata, K. (1988). Some properties and the inclusion behavior of branched cyclodextrins. Chem. Pharm. Bull., 36, 2176-2185.
13. Koizumi, K., Okada, Y., Kubota, Y., Utamura, T. (1987). Inclusion complexes of poorly water-soluble drugs with glucosyl-cyclodextrins. Chem. Pharm. Bull., 35, 3413-3418.
14. Oda, Y., Yanagisawa, H., Maruyama, M., Hattori, K., Yamanoi, T. (2008). Design, synthesis and evaluation of D-galactose-b-cyclodextrin conjugates as drug-carrying molecules. Bioorg. Med. Chem., 16, 8830-8840.
15. Nishi, Y., Tanimoto, T. (2009). Preparation and characterization of branched b-cyclodextrins having a-L-fucopyranose and a study of their functions. Biosci. Biotechnol. Biochem., 73, 562-569.
16. Nishi, Y., Yamane, N., Tanimoto, T. (2007). Preparation and characterization of 6I,6n-di-O-(L-fucopyranosyl)-b-cyclodextrin (n 1/4 II-IV) and investigation of their functions. Carbohydr. Res., 342, 2173-2181.
17. Salmaso, S., Bersani, S., Semenzato, A., Caliceti, P. (2007). New cyclodextrin bioconjugates for active tumour targeting. J. Drug Target., 15, 379-390.
18. Salmaso, S., Semenzato, A., Caliceti, P., Hoebeke, J., Sonvico, F., Dubernet, C., Couvreur, P. (2004). Specific antitumor targetable b-cyclodextrin-poly(ethylene glycol)-folic acid drug delivery bioconjugate. Bioconjugate Chem., 15, 997-1004.
19. Liu, Y., Chen, G.S., Chen, Y., Cao, D.X., Ge, Z.Q., Yuan, Y.J. (2004). Inclusion complexes of paclitaxel and oligo(ethylenediamino) bridged bis(b-cyclodextrin)s: solubilization and antitumor activity. Bioorg. Med. Chem., 12, 5767-5775.
20. Hirayama, F. (1993). Development and pharmaceutical evaluation of hydrophobic cyclodextrin derivatives as modifiedrelease drug carriers. Yakugaku Zasshi, 113, 425-437.
21. Szejtli, J. (1994). Medicinal applications of cyclodextrins. Med. Res. Rev., 14, 353-386.
22. Loftsson, T., Jarho, P., Másson, M., Järvinen, T. (2005). Cyclodextrins in drug delivery. Expert Opin. Drug Deliv., 2, 335-351.
23. Shimpi, S., Chauhan, B., Shimpi, P. (2005). Cyclodextrins: application in different routes of drug administration. Acta Pharm., 55, 139-156.
24. Challa, R., Ahuja, A., Ali, J., Khar, R.K. (2005). Cyclodextrins in drug delivery: an updated review. AAPS PharmSciTech, 6, E329-E357.
25. Yano, H., Hirayama, F., Kamada, M., Arima, H., Uekama, K. (2002). Colon-specific delivery of prednisolone-appended a-cyclodextrin conjugate: alleviation of systemic side effect after oral administration. J. Control. Release, 79, 103-112.
26. Yano, H., Hirayama, F., Arima, H., Uekama, K. (2001). Prednisolone-appended a-cyclodextrin: alleviation of systemic adverse effect of prednisolone after intracolonic administration in 2,4,6-trinitrobenzenesulfonic acid-induced colitis rats. J. Pharm. Sci., 90, 2103-2112.
27. Yano, H., Hirayama, F., Arima, H., Uekama, K. (2001). Preparation of prednisolone-appended a-, b-, and c-cyclodextrins: substitution at secondary hydroxyl groups and in vitro hydrolysis behavior. J. Pharm. Sci., 90, 493-503.
28. Minami, K., Hirayama, F., Uekama, K. (1998). Colon-specific drug delivery based on a cyclodextrin prodrug: release behavior of biphenylylacetic acid from its cyclodextrin conjugates in rat intestinal tracts after oral administration. J. Pharm. Sci., 87, 715-720.
29. Kamada, M., Hirayama, F., Udo, K., Yano, H., Arima, H., Uekama, K. (2002). Cyclodextrin conjugate-based controlled release system: repeated-and prolonged-releases of ketoprofen after oral administration in rats. J. Control. Release, 82, 407-416.
30. Hirayama, F., Ogata, T.,Yano, H., Arima, H., Udo, K., Takano, M., Uekama, K. (2000). Release characteristics of a shortchain fatty acid, n-butyric acid, from its b-cyclodextrin ester conjugate in rat biological media. J. Pharm. Sci., 89, 1486-1495.
31. Yang, C., Li, H., Wang, X., Li, J. (2009). Cationic supramolecules consisting of oligoethylenimine-grafted a-cyclodextrins threaded on poly(ethylene oxide) for gene delivery. J. Biomed. Mater. Res. A, 89, 13-23.
32. Burckbuchler, V., Wintgens, V., Leborgne, C., Lecomte, S., Leygue, N., Scherman, D., Kichler, A., Amiel, C. (2008). Development and characterization of new cyclodextrin polymer-based DNA delivery systems. Bioconjugate Chem., 19, 2311-2320.
33. Tsutsumi, T., Hirayama, F., Uekama, K., Arima, H. (2008). Potential use of polyamidoamine dendrimer/a-cyclodextrin conjugate (generation 3, G3) as a novel carrier for short hairpin RNA-expressing plasmid DNA. J. Pharm. Sci., 97, 3022-3034.
34. Tsutsumi, T., Hirayama, F., Uekama, K., Arima, H. (2007). Evaluation of polyamidoamine dendrimer/a-cyclodextrin conjugate (generation 3, G3) as a novel carrier for small interfering RNA (siRNA). J. Control. Release, 119, 349-359.
35. Arima, H. (2004). Polyfection as nonviral gene transfer method: design of novel nonviral vector using a-cyclodextrin. Yakugaku Zasshi, 124, 451-464.
36. Davis, M.E., Brewster, M.E. (2004). Cyclodextrin-based pharmaceutics: past, present and future. Nat. Rev. Drug Discov., 3, 1023-1035.
37. Higashi, T., Hirayama, F., Arima, H., Uekama, K. (2007). Polypseudorotaxanes of pegylated insulin with cyclodextrins: application to sustained release system. Bioorg. Med. Chem. Lett., 17, 1871-1874.
38. Higashi, T., Hirayama, F., Misumi, S., Arima, H., Uekama, K. (2008). Design and evaluation of polypseudorotaxanes of pegylated insulin with cyclodextrins as sustained release system. Biomaterials, 29, 3866-3871.
39. Yamashita, A., Choi, H.S., Ooya, T., Yui, N., Akita, H., Kogure, K., Harashima, H. (2006). Improved cell viability of linear polyethylenimine through c-cyclodextrin inclusion for effective gene delivery. ChemBioChem, 7, 297-302.
40. Uekama, K., Irie, T., Sunada, M., Otagiri, M., Iwasaki, K., Okano, Y., Miyata, T., Kase, Y. (1981). Effects of cyclodextrins on chlorpromazine-induced haemolysis and central nervous system responses. J. Pharm. Pharmacol., 33, 707-710.
41. Irie, T., Sunada, M., Otagiri, M., Uekama, K. (1983). Protective mechanism of b-cyclodextrin for the hemolysis induced with phenothiazine neuroleptics in vitro. J. Pharmacobio-Dyn., 6, 408-414.
42. Uekama, K., Irie, T., Sunada, M., Otagiri, M., Tsubaki, K. (1981). Protective effects of cyclodextrins on drug-induced hemolysis in vitro. J. Pharmacobio-Dyn., 4, 142-144.
43. Panini, R., Vandelli, M.A., Leo, E., Salvioli, G., Cameroni, R. (1996). The influence of 2-hydroxypropyl-b-cyclodextrin on the haemolysis induced by bile acids. J. Pharm. Pharmacol., 48, 641-644.
44. Funasaki, N., Okuda, T., Neya, S. (2001). Mechanisms and surface chemical prediction of imipramine-induced hemolysis suppressed by modified cyclodextrins. J. Pharm. Sci., 90, 1056-1065.
45. Nagase, Y., Hirata, M., Arima, H., Tajiri, S., Nishimoto, Y., Hirayama, F., Irie, T., Uekama, K. (2002). Protective effect of sulfobutyl ether b-cyclodextrin on DY-9760e-induced hemolysis in vitro. J. Pharm. Sci., 91, 2382-2389.
46. Ohtani,Y., Irie, T., Uekama, K., Fukunaga, K., Pitha, J. (1989). Differential effects of a-, b-and c-cyclodextrins on human erythrocytes. Eur. J. Biochem., 186, 17-22.
47. Debouzy, J.C., Crouzier, D., Dabouis, V., Gadelle, A. (2008). [Per(6-deoxy) derivative of b-cyclodextrin (B6): physicochemical characterization, haemolytic activity and membrane properties]. Ann. Pharm. Fr., 66, 19-27.
48. Weisz, P.B., Kumor, K., Macarak, E.J. (1993). Protection of erythrocytes against hemolytic agents by cyclodextrin polysulfate. Biochem. Pharmacol., 45, 1011-1016.
49. Irie, T., Uekama, K. (1997). Pharmaceutical applications of cyclodextrins: III. Toxicological issues and safety evaluation. J. Pharm. Sci., 86, 147-162.
50. Motoyama, K., Arima, H., Toyodome, H., Irie, T., Hirayama, F., Uekama, K. (2006). Effect of 2,6-di-O-methyl-a-cyclodextrin on hemolysis and morphological change in rabbit's red blood cells. Eur. J. Pharm. Sci., 29, 111-119.
51. Motoyama, K., Toyodome, H., Onodera, R., Irie, T., Hirayama, F., Uekama, K., Arima, H. (2009). Involvement of lipid rafts of rabbit red blood cells in morphological changes induced by methylated b-cyclodextrins. Biol. Pharm. Bull., 32, 700-705.
52. Arima, H., Hirayama, F., Okamoto, C.T., Uekama, K. (2002). Recent aspects of cyclodextrin-based pharmaceutical formulations. Recent Res. Dev. Chem. Pharm. Sci., 2, 155-193.
53. Arima, H., Uekama, K. (2007). In: Touitou, E., Barry, B.W. Eds., Enhancement in Drug Delivery. CRC Press, London, pp. 147-172.
54. Okada, Y., Matsuda, K., Hara, K., Hamayasu, K., Hashimoto, H., Koizumi, K. (1999). Properties and the inclusion behavior of 6-O-a-D-galactosyl-and 6-O-a-D-mannosyl-cyclodextrins. Chem. Pharm. Bull., 47, 1564-1568.
55. Okada,Y., Semma, M., Ichikawa, A. (2007). Physicochemical and biological properties of 6(1),6(3),6(5)-tri-O-a-maltosylcyclomaltoheptaose (6(1),6(3),6(5)-tri-O-a-maltosyl-b-cyclodextrin). Carbohydr. Res., 342, 1315-1322.
56. Attioui, F., al-Omar, A., Leray, E., Parrot-Lopez, H., Finance, C., Bonaly, R. (1994). Recognition ability and cytotoxicity of some oligosaccharidyl substituted b-cyclodextrins. Biol. Cell, 82, 161-167.
57. Irie, T., Uekama, K. (1999). Cyclodextrins in peptide and protein delivery. Adv. Drug Deliv. Rev., 36, 101-123.
58. Ohkubo, S., Nakahata, N. (2007). Role of lipid rafts in trimeric G protein-mediated signal transduction. Yakugaku Zasshi, 127, 27-40.
59. Delmas, O., Breton, M., Sapin, C., Le Bivic, A., Colard, O., Trugnan, G. (2007). Heterogeneity of raft-type membrane microdomains associated with VP4, the rotavirus spike protein, in Caco-2 and MA 104 cells. J. Virol., 81, 1610-1618.
60. Fauvelle, F., Debouzy, J.C., Crouzy, S., Goschl, M., Chapron, Y. (1997). Mechanism of a-cyclodextrin-induced hemolysis: 1. The two-step extraction of phosphatidylinositol from the membrane. J. Pharm. Sci., 86, 935-943.
61. Monnaert, V., Tilloy, S., Bricout, H., Fenart, L., Cecchelli, R., Monflier, E. (2004). Behavior of a-, b-, and c-cyclodextrins and their derivatives on an in vitro model of blood-brain barrier. J. Pharmacol. Exp. Ther., 310, 745-751.
62. Arima, H., Yunomae, K., Hirayama, F., Uekama, K. (2001). Contribution of P-glycoprotein to the enhancing effects of dimethyl-b-cyclodextrin on oral bioavailability of tacrolimus. J. Pharmacol. Exp. Ther., 297, 547-555.
63. Ono, N., Arima, H., Hirayama, F., Uekama, K. (2001). A moderate interaction of maltosyl-a-cyclodextrin with Caco-2 cells in comparison with the parent cyclodextrin. Biol. Pharm. Bull., 24, 395-402.
64. Boulmedarat, L., Bochot, A., Lesieur, S., Fattal, E. (2005). Evaluation of buccal methyl-b-cyclodextrin toxicity on human oral epithelial cell culture model. J. Pharm. Sci., 94, 1300-1309.
65. Kiss, T., Fenyvesi, F., Pasztor, N., Feher, P.,Varadi, J.,Kocsan, R., Szente, L., Fenyvesi, E., Szabo, G., Vecsernyes, M., Bacskay, I. (2007). Cytotoxicity of different types of methylated b-cyclodextrins and ionic derivatives. Pharmazie, 62, 557-558.
66. Motoyama, K., Kameyama, K., Onodera, R., Araki, N., Hirayama, F., Uekama, K., Arima, H. (2009). Involvement of PI3K-Akt-Bad pathway in apoptosis induced by 2,6-di-Omethyl-b-cyclodextrin, not 2,6-di-O-methyl-a-cyclodextrin, through cholesterol depletion from lipid rafts on plasma membranes in cells. Eur. J. Pharm. Sci., 38, 249-261.
67. Ulloth, J.E., Almaguel, F.G., Padilla, A., Bu, L., Liu, J.W., De Leon, M. (2007). Characterization of methyl-b-cyclodextrin toxicity in NGF-differentiated PC12 cell death. Neurotoxicology, 28, 613-621.
68. Hipler, U.C., Schonfelder, U., Hipler, C., Elsner, P. (2007). Influence of cyclodextrins on the proliferation of HaCaT keratinocytes in vitro. J. Biomed. Mater. Res. A, 83, 70-79.
69. Abrami, L., van Der Goot, F. G. (1999). Plasma membrane microdomains act as concentration platforms to facilitate intoxication by aerolysin. J. Cell Biol., 147, 175-184.
70. Nelson, K.L., Buckley, J.T. (2000). Channel formation by the glycosylphosphatidylinositol-anchored protein binding toxin aerolysin is not promoted by lipid rafts. J. Biol. Chem., 275, 19839-19843.
71. Gosens, R., Stelmack, G.L., Dueck, G., Mutawe, M.M., Hinton, M., McNeill, K.D., Paulson, A., Dakshinamurti, S., Gerthoffer, W.T., Thliveris, J.A., Unruh, H., Zaagsma, J., Halayko, A.J. (2007). Caveolae facilitate muscarinic receptor-mediated intracellular Ca2{thorn} mobilization and contraction in airway smooth muscle. Am. J. Physiol. Lung Cell Mol. Physiol., 293, L1406-L1418.
72. Han, W., Li, H., Villar, V.A., Pascua, A.M., Dajani, M.I., Wang, X., Natarajan, A., Quinn, M.T., Felder, R.A., Jose, P.A., Yu, P. (2008). Lipid rafts keep NADPH oxidase in the inactive state in human renal proximal tubule cells. Hypertension, 51, 481-487.
73. Kincer, J.F., Uittenbogaard, A., Dressman, J., Guerin, T.M., Febbraio, M., Guo, L., Smart, E.J. (2002). Hypercholesterolemia promotes a CD36-dependent and endothelial nitricoxide synthase-mediated vascular dysfunction. J. Biol. Chem., 277, 23525-23533.
74. Camargo, F., Erickson, R.P., Garver, W.S., Hossain, G.S., Carbone, P.N., Heidenreich, R.A., Blanchard, J. (2001). Cyclodextrins in the treatment of a mouse model of Niemann--Pick C disease. Life Sci., 70, 131-142.
75. Zhang, Q., Furukawa, K., Chen, H.H., Sakakibara, T., Urano, T., Furukawa, K. (2006). Metastatic potential of mouse Lewis lung cancer cells is regulated via ganglioside GM1 by modulating the matrix metalloprotease-9 localization in lipid rafts. J. Biol. Chem., 281, 18145-18155.
76. Kritharides, L., Kus, M., Brown, A.J., Jessup, W., Dean, R.T. (1996). Hydroxypropyl-b-cyclodextrin-mediated efflux of 7-ketocholesterol from macrophage foam cells. J. Biol. Chem., 271, 27450-27455.
77. Arima, H., Nishimoto, Y., Motoyama, K., Hirayama, F., Uekama, K. (2001). Inhibitory effects of novel hydrophilic cyclodextrin derivatives on nitric oxide production in macrophages stimulated with lipopolysaccharide. Pharm. Res., 18, 1167-1173.
78. Totterman, A.M., Schipper, N.G., Thompson, D.O., Mannermaa, J.P. (1997). Intestinal safety of water-soluble b-cyclodextrins in paediatric oral solutions of spironolactone: effects on human intestinal epithelial Caco-2 cells. J. Pharm. Pharmacol., 49, 43-48.
79. Zhao, Q., Temsamani, J., Agrawal, S. (1995). Use of cyclodextrin and its derivatives as carriers for oligonucleotide delivery. Antisense Res. Dev., 5, 185-192.
80. Grosse, P.Y., Bressolle, F., Pinguet, F. (1997). Methyl-b-cyclodextrin in HL-60 parental and multidrug-resistant cancer cell lines: effect on the cytotoxic activity and intracellular accumulation of doxorubicin. Cancer Chemother. Pharmacol., 40, 489-494.
81. Kang, J., Kumar, V., Yang, D., Chowdhury, P.R., Hohl, R.J. (2002). Cyclodextrin complexation: influence on the solubility, stability, and cytotoxicity of camptothecin, an antineoplastic agent. Eur. J. Pharm. Sci., 15, 163-170.
82. Yunomae, K., Arima, H., Hirayama, F., Uekama, K. (2003). Involvement of cholesterol in the inhibitory effect of dimethyl-b-cyclodextrin on P-glycoprotein and MRP2 function in Caco-2 cells. FEBS Lett., 536, 225-231.
83. Fenyvesi, F., Fenyvesi, E., Szente, L., Goda, K., Bacso, Z., Bacskay, I., Varadi, J., Kiss, T., Molnar, E., Janaky, T., Szabo, G., Jr., Vecsernyes, M. (2008). P-glycoprotein inhibition by membrane cholesterol modulation. Eur. J. Pharm. Sci., 34, 236-242.
84. Balijepalli, R.C., Foell, J.D., Hall, D.D., Hell, J.W., Kamp, T.J. (2006). Localization of cardiac L-type Ca2{thorn} channels to a caveolar macromolecular signaling complex is required for b2-adrenergic regulation. Proc. Natl. Acad. Sci. USA, 103, 7500-7505.
85. Abulrob, A., Tauskela, J.S., Mealing, G., Brunette, E., Faid, K., Stanimirovic, D. (2005). Protection by cholesterol-extracting cyclodextrins: a role for N-methyl-D-aspartate receptor redistribution. J. Neurochem., 92, 1477-1486.
86. Hill, W.G., Butterworth, M.B., Wang, H., Edinger, R.S., Lebowitz, J., Peters, K.W., Frizzell, R.A., Johnson, J.P. (2007). The epithelial sodium channel (ENaC) traffics to apical membrane in lipid rafts in mouse cortical collecting duct cells. J. Biol. Chem., 282, 37402-37411.
87. Ahsan, F., Arnold, J.J., Yang, T., Meezan, E., Schwiebert, E.M., Pillion, D.J. (2003). Effects of the permeability enhancers, tetradecylmaltoside and dimethyl-b-cyclodextrin, on insulin movement across human bronchial epithelial cells (16HBE14o-). Eur. J. Pharm. Sci., 20, 27-34.
88. Monnaert,V., Betbeder, D., Fenart, L., Bricout, H., Lenfant, A. M., Landry, C., Cecchelli, R., Monflier, E., Tilloy, S. (2004). Effects of c-and hydroxypropyl-c-cyclodextrins on the transport of doxorubicin across an in vitro model of blood-brain barrier. J. Pharmacol. Exp. Ther., 311, 1115-1120.
89. Bar, R., Ulitzur, S. (1994). Bacterial toxicity of cyclodextrins: luminuous Escherichia coli as a model. Appl. Microbiol. Biotechnol., 41, 574-577.
90. Zhang, H.M., Li, Z., Uematsu, K., Kobayashi, T., Horikoshi, K. (2008). Antibacterial activity of cyclodextrins against Bacillus strains. Arch. Microbiol., 190, 605-609.
91. Aachmann, F.L., Aune, T.E. (2009). Use of cyclodextrin and its derivatives for increased transformation efficiency of competent bacterial cells. Appl. Microbiol. Biotechnol., 83, 589-596.
92. Donova, M.V., Nikolayeva, V.M., Dovbnya, D.V., Gulevskaya, S.A., Suzina, N.E. (2007). Methyl-b-cyclodextrin alters growth, activity and cell envelope features of sterol-transforming mycobacteria. Microbiology, 153, 1981-1992.
93. Hang'ombe, M.B., Mukamoto, M., Kohda, T., Sugimoto, N., Kozaki, S. (2004). Cytotoxicity of Clostridium septicum a-toxin: its oligomerization in detergent resistant membranes of mammalian cells. Microb. Pathog., 37, 279-286.
94. Nagahama, M., Yamaguchi, A., Hagiyama, T., Ohkubo, N., Kobayashi, K., Sakurai, J. (2004). Binding and internalization of Clostridium perfringens i-toxin in lipid rafts. Infect. Immun., 72, 3267-3275.
95. Karginov, V.A., Nestorovich, E.M., Schmidtmann, F., Robinson, T.M., Yohannes, A., Fahmi, N.E., Bezrukov, S.M., Hecht, S.M. (2007). Inhibition of S. aureus a-hemolysin and B. anthracis lethal toxin by b-cyclodextrin derivatives. Bioorg. Med. Chem., 15, 5424-5431.
96. Giesemann, T., Jank, T., Gerhard, R., Maier, E., Just, I., Benz, R., Aktories, K. (2006). Cholesterol-dependent pore formation of Clostridium difficile toxin A. J. Biol. Chem., 281, 10808-10815.
97. Miyata, S., Minami, J., Tamai, E., Matsushita, O., Shimamoto, S., Okabe, A. (2002). Clostridium perfringens e-toxin forms a heptameric pore within the detergent-insoluble microdomains of Madin-Darby canine kidney cells and rat synaptosomes. J. Biol. Chem., 277, 39463-39468.
98. Zhuang, M., Oltean, D.I., Gomez, I., Pullikuth, A.K., Soberon, M., Bravo, A., Gill, S.S. (2002). Heliothis virescens and Manduca sexta lipid rafts are involved in Cry1A toxin binding to the midgut epithelium and subsequent pore formation. J. Biol. Chem., 277, 13863-13872.
99. Boesze-Battaglia, K., Besack, D., McKay, T., Zekavat, A., Otis, L., Jordan-Sciutto, K., Shenker, B.J. (2006). Cholesterolrich membrane microdomains mediate cell cycle arrest induced by Actinobacillus actinomycetemcomitans cytolethaldistending toxin. Cell Microbiol., 8, 823-836.
100. Schroeder, G.N., Hilbi, H. (2007). Cholesterol is required to trigger caspase-1 activation and macrophage apoptosis after phagosomal escape of Shigella. Cell Microbiol., 9, 265-278.
101. Moriyama, T., Marquez, J.P., Wakatsuki, T., Sorokin, A. (2007). Caveolar endocytosis is critical for BK virus infection of human renal proximal tubular epithelial cells. J. Virol., 81, 8552-8562.
102. Zaidi, T., Bajmoczi, M., Zaidi, T., Golan, D.E., Pier, G.B. (2008). Disruption of CFTR-dependent lipid rafts reduces bacterial levels and corneal disease in a murine model of Pseudomonas aeruginosa keratitis. Invest. Ophthalmol. Vis. Sci., 49, 1000-1009.
103. Chassin, C.,Vimont, S., Cluzeaud, F., Bens, M., Goujon, J.M., Fernandez, B., Hertig, A., Rondeau, E., Arlet, G., Hornef, M. W., Vandewalle, A. (2008). TLR4 facilitates translocation of bacteria across renal collecting duct cells. J. Am. Soc. Nephrol., 19, 2364-2374.
104. Schraw,W., Li, Y., McClain, M.S., van der Goot, F.G., Cover, T.L. (2002). Association of Helicobacter pylori vacuolating toxin (VacA) with lipid rafts. J. Biol. Chem., 277, 34642-34650.
105. Patel, H.K., Willhite, D.C., Patel, R.M., Ye, D., Williams, C.L., Torres, E.M., Marty, K.B., MacDonald, R.A., Blanke, S.R. (2002). Plasma membrane cholesterol modulates cellular vacuolation induced by the Helicobacter pylori vacuolating cytotoxin. Infect. Immun., 70, 4112-4123.
106. Petro, K.A., Dyer, M.A., Yowler, B.C., Schengrund, C.L. (2006). Disruption of lipid rafts enhances activity of botulinum neurotoxin serotype A. Toxicon, 48, 1035-1045.
107. Karginov, V.A., Nestorovich, E.M., Moayeri, M., Leppla, S.H., Bezrukov, S.M. (2005). Blocking anthrax lethal toxin at the protective antigen channel by using structure-inspired drug design. Proc. Natl. Acad. Sci. USA, 102, 15075-15080.
108. Karginov, V.A., Nestorovich, E.M., Yohannes, A., Robinson, T.M., Fahmi, N.E., Schmidtmann, F., Hecht, S.M., Bezrukov, S.M. (2006). Search for cyclodextrin-based inhibitors of anthrax toxins: synthesis, structural features, and relative activities. Antimicrob. Agents Chemother., 50, 3740-3753.
109. Backer, M.V., Patel,V., Jehning, B.T., Claffey, K.P., Karginov, V.A., Backer, J.M. (2007). Inhibition of anthrax protective antigen outside and inside the cell. Antimicrob. Agents Chemother., 51, 245-251.
110. Takeda, K., Akira, S. (2007). Toll-like receptors. In: Current Protocols in Immunology. Unit 14.12. Coligan JE, Ed. Hoboken, NJ: Wiley.
111. Parkinson, T. (2008). The future of Toll-like receptor therapeutics. Curr. Opin. Mol. Ther., 10, 21-31.
112. Lancaster, G.I., Khan, Q., Drysdale, P.,Wallace, F., Jeukendrup, A.E., Drayson, M.T., Gleeson, M. (2005). The physiological regulation of Toll-like receptor expression and function in humans. J. Physiol., 563, 945-955.
113. Motoyama, K., Hashimoto, Y., Hirayama, F., Uekama, K., Arima, H. (2009). Inhibitory effects of 2,6-di-O-methyl-a-cyclodextrin on poly I: C signaling in macrophages. Eur. J. Pharm. Sci., 36, 285-291.
114. Arima, H., Motoyama, K., Matsukawa, A., Nishimoto, Y., Hirayama, F., Uekama, K. (2005). Inhibitory effects of dimethylacetyl-b-cyclodextrin on lipopolysaccharide-induced macrophage activation and endotoxin shock in mice. Biochem. Pharmacol., 70, 1506-1517.
115. Imaizumi, A., Suzuki, Y., Ono, S., Sato, H., Sato, Y. (1983). Effect of heptakis (2,6-O-dimethyl) b-cyclodextrin on the production of pertussis toxin by Bordetella pertussis. Infect. Immun., 41, 1138-1143.
116. Morshed, M.G., Karita, M.,Konishi, H., Okita, K., Nakazawa, T. (1994). Growth medium containing cyclodextrin and low concentration of horse serum for cultivation of Helicobacter pylori. Microbiol. Immunol., 38, 897-900.
117. Marchini, A., d'Apolito, M., Massari, P., Atzeni, M., Copass, M., Olivieri, R. (1995). Cyclodextrins for growth of Helicobacter pylori and production of vacuolating cytotoxin. Arch. Microbiol., 164, 290-293.
118. Lin, Z., Kong, D., Zhong, P., Yin, K., Dong, L. (2005). Influence of hydroxypropylcyclodextrins on the toxicity of mixtures. Chemosphere, 58, 1301-1306.
119. Stella, V.J., He, Q. (2008). Cyclodextrins. Toxicol. Pathol., 36, 30-42.
120. Gould, S., Scott, R.C. (2005). 2-Hydroxypropyl-b-cyclodextrin (HP-b-CD): a toxicology review. Food Chem. Toxicol., 43, 1451-1459.
121. Uekama, K., Hirayama, F. (2003). Improvement of Drug Properties by Cyclodextrins. Elsevier, Amsterdam, pp. 671-696.
122. Frank, D.W., Gray, J.E., Weaver, R.N. (1976). Cyclodextrin nephrosis in the rat. Am. J. Pathol., 83, 367-382.
123. Hiasa, Y., Ohshima, M., Kitahori, Y., Konishi, N., Fujita, T., Yuasa, T. (1982). b-Cyclodextrin: promoting effect on the development of renal tubular cell tumors in rats treated withNethyl-N-hydroxyethylnitrosamine. J. Natl. Cancer Inst., 69, 963-967.
124. Rajewski, R.A., Traiger, G., Bresnahan, J., Jaberaboansari, P., Stella, V.J., Thompson, D.O. (1995). Preliminary safety evaluation of parenterally administered sulfoalkyl ether b-cyclodextrin derivatives. J. Pharm. Sci., 84, 927-932.
125. von Mach, M.A., Burhenne, J., Weilemann, L.S. (2006). Accumulation of the solvent vehicle sulphobutylether b cyclodextrin sodium in critically ill patients treated with intravenous voriconazole under renal replacement therapy. BMC Clin. Pharmacol., 6, 6.
126. McIntosh, M.P., Schwarting, N., Rajewski, R.A. (2004). In vitro and in vivo evaluation of a sulfobutyl ether b-cyclodextrin enabled etomidate formulation. J. Pharm. Sci., 93, 2585-2594.
127. Kim, Y., Oksanen, D.A., Massefski,W., Jr., Blake, J.F., Duffy, E.M., Chrunyk, B. (1998). Inclusion complexation of ziprasidone mesylate with b-cyclodextrin sulfobutyl ether. J. Pharm. Sci., 87, 1560-1567.
128. Yaksh, T.L., Jang, J.D., Nishiuchi, Y., Braun, K.P., Ro, S.G., Goodman, M. (1991). The utility of 2-hydroxypropyl-b-cyclodextrin as a vehicle for the intracerebral and intrathecal administration of drugs. Life Sci., 48, 623-633.
129. Debouzy, J.C., Gadelle, A., Tymen, H., Le Gall, B., Millot, X., Moretto, P., Fauvelle, F., Le Peoc, H.M., Dabouis, V., Martel, B. (2003). In vitro uranyle affinity of per(3,6-anhydro-2-Ocarboxymethyle)-a-cyclodextrin and conditions required for in vivo application. Ann. Pharm. Fr., 61, 62-69.
130. Naguib, M. (2007). Sugammadex: another milestone in clinical neuromuscular pharmacology. Anesth. Analg., 104, 575-581.
131. Vanacker, B.F., Vermeyen, K.M., Struys, M.M., Rietbergen, H., Vandermeersch, E., Saldien, V., Kalmar, A.F., Prins, M.E. (2007). Reversal of rocuronium-induced neuromuscular block with the novel drug sugammadex is equally effective under maintenance anesthesia with propofol or sevoflurane. Anesth. Analg., 104, 563-568.
132. Puhringer, F.K., Rex, C., Sielenkamper, A.W., Claudius, C., Larsen, P.B., Prins, M.E., Eikermann, M., Khuenl-Brady, K.S. (2008). Reversal of profound, high-dose rocuronium-induced neuromuscular blockade by sugammadex at two different time points: an international, multicenter, randomized, dose-finding, safety assessor-blinded, phase II trial. Anesthesiology, 109, 188-197.
133. Cammu, G., De Kam, P.J., Demeyer, I., Decoopman, M., Peeters, P.A., Smeets, J.M., Foubert, L. (2008). Safety and tolerability of single intravenous doses of sugammadex administered simultaneously with rocuronium or vecuronium in healthy volunteers. Br. J. Anaesth., 100, 373-379.
134. Mirakhur, R.K. (2009). Sugammadex in clinical practice. Anaesthesia, 64 (Suppl. 1), 45-54.
135. Lina, B.A., Bar, A. (2004). Subchronic oral toxicity studies with a-cyclodextrin in rats. Regul. Toxicol. Pharmacol., 39 (Suppl. 1), S14-S26.
136. Waalkens-Berendsen, D.H., Bar, A. (2004). Embryotoxicity and teratogenicity study with a-cyclodextrin in rats. Regul. Toxicol. Pharmacol., 39 (Suppl. 1), S34-S39.
137. Waalkens-Berendsen, D.H., Smits-Van Prooije, A.E., Bar, A. (2004). Embryotoxicity and teratogenicity study with a-cyclodextrin in rabbits.Regul.Toxicol.Pharmacol., 39 (Suppl. 1), S40-S46.
138. Szejtli, J. (1988). In: Davies, J.E.D. Ed., Cyclodextrin Technology. Kluwer, Dordrecht, The Netherlands.
139. Bellringer, M.E., Smith, T.G., Read, R., Gopinath, C., Olivier, P. (1995). b-Cyclodextrin:52-week toxicity studies in the rat and dog. Food Chem. Toxicol., 33, 367-376.
140. Toyoda, K., Shoda, T., Uneyama, C., Takada, K., Takahashi, M. (1997). Carcinogenicity study of b-cyclodextrin in F344 rats. Food Chem. Toxicol., 35, 331-336.
141. Waner, T., Borelli, G., Cadel, S., Privman, I., Nyska, A. (1995). Investigation of potential oncogenetic effects of b-cyclodextrin in the rat and mouse. Arch. Toxicol., 69, 631-639.
142. Toyoda, K., Hayashi, S., Uneyama, C., Kawanishi, T., Takada, K., Takahashi, M. (1995). Hepatic lesions in F344 rats treated orally with b-cyclodextrin for 13 weeks. Eisei Shikenjo Hokoku, 36-43.
143. Barrow, P.C., Olivier, P., Marzin, D. (1995). The reproductive and developmental toxicity profile of b-cyclodextrin in rodents. Reprod. Toxicol., 9, 389-398.
144. Garcia-Mediavilla, V., Villares, C., Culebras, J.M., Bayon, J. E., Gonzalez-Gallego, J. (2003). Effects of dietary b-cyclodextrin in hypercholesterolaemic rats. Pharmacol. Toxicol., 92, 94-99.
145. Munro, I.C., Newberne, P.M., Young, V.R., Bar, A. (2004). Safety assessment of c-cyclodextrin. Regul. Toxicol. Pharmacol., 39 (Suppl. 1), S3-S13.
146. Waalkens-Berendsen, D.H., Verhagen, F.J., Bar, A. (1998). Embryotoxicity and teratogenicity study with c-cyclodextrin in rats. Regul. Toxicol. Pharmacol., 27, 166-171.
147. Waalkens-Berendsen, D.H., Smits van Prooije, A.E., Bar, A. (1998). Embryotoxicity and teratogenicity study with c-cyclodextrin in rabbits. Regul. Toxicol. Pharmacol., 27, 172-177.
148. Shao, Z., Li, Y., Chermak, T., Mitra, A.K. (1994). Cyclodextrins as mucosal absorption promoters of insulin: II. Effects of b-cyclodextrin derivatives on a-chymotryptic degradation and enteral absorption of insulin in rats. Pharm. Res., 11, 1174-1179.
149. Somogyi, G., Posta, J., Buris, L., Varga, M. (2006). Cyclodextrin (CD) complexes of cholesterol: their potential use in reducing dietary cholesterol intake. Pharmazie, 61, 154-156.
150. Rajewski, R.A., Stella, V.J. (1996). Pharmaceutical applications of cyclodextrins: 2. In vivo drug delivery. J. Pharm. Sci., 85, 1142-1169.
151. Okada, S.S., Kuo, A., Muttreja, M.R., Hozakowska, E.,Weisz, P.B., Barnathan, E.S. (1995). Inhibition of human vascular smooth muscle cell migration and proliferation by b-cyclodextrin tetradecasulfate. J. Pharmacol. Exp. Ther., 273, 948-954.
152. Song, Y., Wang, Y., Thakur, R., Meidan, V.M., Michniak, B. (2004). Mucosal drug delivery: membranes, methodologies, and applications. Crit. Rev. Ther. Drug Carrier Syst., 21, 195-256.
153. Costantino, H.R., Illum, L., Brandt, G., Johnson, P.H., Quay, S.C. (2007). Intranasal delivery: physicochemical and therapeutic aspects. Int. J. Pharm., 337, 1-24.
154. Merkus, F.W., Verhoef, J.C., Marttin, E., Romeijn, S.G., van der Kuy, P.H., Hermens,W.A., Schipper, N.G. (1999). Cyclodextrins in nasal drug delivery. Adv. Drug Deliv. Rev., 36, 41-57.
155. Uchenna Agu, R., Jorissen, M.,Willems, T., Van den Mooter, G., Kinget, R., Verbeke, N., Augustijns, P. (2000). Safety assessment of selected cyclodextrins: effect on ciliary activity using a human cell suspension culture model exhibiting in vitro ciliogenesis. Int. J. Pharm., 193, 219-226.
156. Asai, K., Morishita, M., Katsuta, H., Hosoda, S., Shinomiya, K., Noro, M., Nagai, T., Takayama, K. (2002). The effects of water-soluble cyclodextrins on the histological integrity of the rat nasal mucosa. Int. J. Pharm., 246, 25-35.
157. Matsubara, K., Abe, K., Irie, T., Uekama, K. (1995). Improvement of nasal bioavailability of luteinizing hormone-releasing hormone agonist, buserelin, by cyclodextrin derivatives in rats. J. Pharm. Sci., 84, 1295-1300.
158. Abe, K., Irie, T., Uekama, K. (1995). Enhanced nasal delivery of luteinizing hormone releasing hormone agonist buserelin by oleic acid solubilized and stabilized in hydroxypropylb-cyclodextrin. Chem. Pharm. Bull., 43, 2232-2237.
159. Ahsan, F., Arnold, J.J., Meezan, E., Pillion, D.J. (2001). Mutual inhibition of the insulin absorption-enhancing properties of dodecylmaltoside and dimethyl-b-cyclodextrin following nasal administration. Pharm. Res., 18, 608-614.
160. Zhao,Y., Zhang, D.W., Zheng, A.P.,Yu, S.Y.,Wu, F.L. (2004). Influence of seven absorption enhancers on nasal mucosa: assessment of toxicity. Beijing Da Xue Xue Bao, 36, 417-420.
161. Gudmundsdóttir, H., Sigurjónsdóttir, J.F., Másson, M., Fjalldal, O., Stefansson, E., Loftsson, T. (2001). Intranasal administration of midazolam in a cyclodextrin based formulation: bioavailability and clinical evaluation in humans. Pharmazie, 56, 963-966.
162. Courrier, H.M., Butz, N., Vandamme, T.F. (2002). Pulmonary drug delivery systems: recent developments and prospects. Crit. Rev. Ther. Drug Carrier Syst., 19, 425-498.
163. Matilainen, L., Toropainen, T., Vihola, H., Hirvonen, J., Jarvinen, T., Jarho, P., Järvinen, K. (2008). In vitro toxicity and permeation of cyclodextrins in Calu-3 cells. J. Control. Release 126, 10-16.
164. Kinnarinen, T., Jarho, P., Järvinen, K., Järvinen, T. (2003). Pulmonary deposition of a budesonide/c-cyclodextrin complex in vitro. J. Control. Release, 90, 197-205.
165. Srichana, T., Suedee, R., Reanmongkol, W. (2001). Cyclodextrin as a potential drug carrier in salbutamol dry powder aerosols: the in-vitro deposition and toxicity studies of the complexes. Respir. Med., 95, 513-519.
166. Fukaya, H., Iimura, A., Hoshiko, K., Fuyumuro, T., Noji, S., Nabeshima, T. (2003).A cyclosporin A/maltosyl-a-cyclodextrin complex for inhalation therapy of asthma. Eur. Respir. J., 22, 213-219.
167. Arima, H., Uekama, K. (2007). Cyclodextrins and Other Enhancers in Rectal Delivery. CRC Press, Boca Raton, FL, pp. 147-172.
168. Arima, H., Kondo, T., Irie, T., Hirayama, F., Uekama, K., Miyaji, T., Inoue, Y. (1992). Use of water-soluble b-cyclodextrin derivatives as carriers of anti-inflammatory drug biphenylylacetic acid in rectal delivery. Yakugaku Zasshi, 112, 65-72.
169. Uekama, K., Kondo, T., Nakamura, K., Irie, T., Arakawa, K., Shibuya, M., Tanaka, J. (1995). Modification of rectal absorption of morphine from hollow-type suppositories with a combination of a-cyclodextrin and viscosity-enhancing polysaccharide. J. Pharm. Sci., 84, 15-20.
170. Gaudana, R., Jwala, J., Boddu, S.H., Mitra, A.K. (2009). Recent perspectives in ocular drug delivery. Pharm. Res., 26, 1197-1216.
171. Kanai, A., Alba, R.M., Takano, T., Kobayashi, C., Nakajima, A., Kurihara, K.,Yokoyama, T., Fukami, M. (1989). The effect on the cornea of a cyclodextrin vehicle for cyclosporin eye drops. Transplant. Proc., 21, 3150-3152.
172. Suhonen, P., Järvinen, T., Lehmussaari, K., Reunamaki, T., Urtti, A. (1995). Ocular absorption and irritation of pilocarpine prodrug is modified with buffer, polymer, and cyclodextrin in the eyedrop. Pharm. Res., 12, 529-533.
173. Wang, S., Li, D., Ito,Y., Nabekura, T.,Wang, S., Zhang, J.,Wu, C. (2004). Bioavailability and anticataract effects of a topical ocular drug delivery system containing disulfiram and hydroxypropyl-b-cyclodextrin on selenite-treated rats. Curr. Eye Res., 29, 51-58.
174. Jarho, P., Järvinen, K., Urtti, A., Stella, V.J., Järvinen, T. (1996). Modified b-cyclodextrin (SBE7-b-CyD) with viscous vehicle improves the ocular delivery and tolerability of pilocarpine prodrug in rabbits. J. Pharm. Pharmacol., 48, 263-269.
175. Järvinen, T., Järvinen, K., Urtti, A., Thompson, D., Stella, V.J. (1995). Sulfobutyl ether b-cyclodextrin (SBE-b-CD) in eyedrops improves the tolerability of a topically applied pilocarpine prodrug in rabbits. J. Ocul. Pharmacol. Ther., 11, 95-106.
176. Jansen, T., Xhonneux, B., Mesens, J., Borgers, M. (1990). b-cyclodextrins as vehicles in eye-drop formulations: an evaluation of their effects on rabbit corneal epithelium. Lens Eye Toxic. Res., 7, 459-468.
177. Brown, M.B., Traynor, M.J., Martin, G.P., Akomeah, F.K. (2008). Transdermal drug delivery systems: skin perturbation devices. Methods Mol. Biol., 437, 119-139.
178. Piel, G., Moutard, S., Uhoda, E., Pilard, F., Pierard, G.E., Perly, B., Delattre, L., Evrard, B. (2004). Skin compatibility of cyclodextrins and their derivatives: a comparative assessment using a corneoxenometry bioassay. Eur. J. Pharm. Biopharm., 57, 479-482.
179. Uekama, K., Irie, T., Sunada, M., Otagiri, M., Arimatsu, Y., Nomura, S. (1982). Alleviation of prochlorperazine-induced primary irritation of skin by cyclodextrin complexation. Chem. Pharm. Bull., 30, 3860-3862.
180. Vollmer, U., Muller, B.W., Wilffert, B., Peters, T. (1993). An improved model for studies on transdermal drug absorption invivo in rats. J. Pharm. Pharmacol., 45, 242-245.
181. Vitoria, M., Bentley, L.B., Vianna, R.F.,Wilson, S., Collett, J. (1997). Characterization of the influence of some cyclodextrins on the stratum corneum from the hairless mouse. J. Pharm. Pharmacol., 49, 39-402.
182. Bentley, M.V., Vianna, R.F., Wilson, S., Collett, J.H. (1997). Characterization of the influence of some cyclodextrins on the stratum corneum from the hairless mouse. J. Pharm. Pharmacol., 49, 397-402.
183. Duchêne, D., Wouessidjewe, D., Poelman, M.C. (1991). In: Duchene, D. Ed., New Trends in Cyclodextrins and Derivatives. Editions de Sante, Paris, pp. 447-481.
184. Woolfson, A.D., Malcolm, R.K., Gallagher, R. (2000). Drug delivery by the intravaginal route. Crit. Rev. Ther. Drug Carrier Syst., 17, 509-555.
185. Francois, M., Snoeckx, E., Putteman, P., Wouters, F., De Proost, E., Delaet, U., Peeters, J., Brewster, M.E. (2003). A mucoadhesive, cyclodextrin-based vaginal cream formulation of itraconazole. AAPS PharmSci, 5, E5.
186. Cevher, E., Sensoy, D., Zloh, M., Mulazimoglu, L. (2008). Preparation and characterisation of natamycin: c-cyclodextrin inclusion complex and its evaluation in vaginal mucoadhesive formulations. J. Pharm. Sci., 97, 4319-4335.
187. Miyake, K., Irie, T., Arima, H., Hirayama, F., Uekama, K., Hirano, M., Okamaoto, Y. (1999). Characterization of itraconazole/2-hydroxypropyl-b-cyclodextrin inclusion complex in aqueous propylene glycol solution. Int. J. Pharm., 179, 237-245.
188. Uekama, K. (2004). Pharmaceutical application of cyclodextrins as multi-functional drug carriers. Yakugaku Zasshi, 124, 909-935.
189. Yano, H., Hirayama, F., Arima, H., Uekama, K. (2000). Hydrolysis behavior of prednisolone 21-hemisuccinate/b-cyclodextrin amide conjugate: involvement of intramolecular catalysis of amide group in drug release. Chem. Pharm. Bull., 48, 1125-1128.
190. Hirayama, F., Uekama, K. (1999). Cyclodextrin-based controlled drug release system. Adv. Drug Deliv. Rev.,36, 125-141.
191. Lowenstein, P.R. (2008). Clinical trials in gene therapy: ethics of informed consent and the future of experimental medicine. Curr. Opin. Mol. Ther., 10, 428-430.
192. Castanotto, D., Rossi, J.J. (2009). The promises and pitfalls of RNA-interference-based therapeutics. Nature, 457, 426-433.
193. Rao, D.D., Vorhies, J.S., Senzer, N., Nemunaitis, J. (2009). siRNA vs. shRNA: similarities and differences. Adv. Drug Deliv. Rev., 61, 746-759.
194. Grimm, D. (2009). Small silencing RNAs: state-of-the-art. Adv. Drug Deliv. Rev., 61, 672-703.
195. Akhtar, S. (2006). Non-viral cancer gene therapy: beyond delivery. Gene Ther., 13, 739-740.
196. Arima, H., Kihara, F., Hirayama, F., Uekama, K. (2001). Enhancement of gene expression by polyamidoamine dendrimer conjugates with a-, b-, and c-cyclodextrins. Bioconjugate Chem., 12, 476-484.
197. Kihara, F., Arima, H., Tsutsumi, T., Hirayama, F., Uekama, K. (2002). Effects of structure of polyamidoamine dendrimer on gene transfer efficiency of the dendrimer conjugate with a-cyclodextrin. Bioconjugate Chem., 13, 1211-1219.
198. Kihara, F., Arima, H., Tsutsumi, T., Hirayama, F., Uekama, K. (2003). In vitro and in vivo gene transfer by an optimized a-cyclodextrin conjugate with polyamidoamine dendrimer. Bioconjugate Chem., 14, 342-350.
199. Arima, H., Motoyama, K. (2009). Recent findings concerning PAMAM dendrimer conjugates with cyclodextrins as carriers of DNA and RNA. Sensors, 9, 6346-6361.
200. Forrest, M.L., Gabrielson, N., Pack, D.W. (2005). Cyclodextrin-polyethylenimine conjugates for targeted in vitro gene delivery. Biotechnol. Bioeng., 89, 416-423.
201. Yang, C.,Wang, X., Li, H., Goh, S.H., Li, J. (2007). Synthesis and characterization of polyrotaxanes consisting of cationic a-cyclodextrins threaded on poly[(ethylene oxide)-ran-(propylene oxide)] as gene carriers. Biomacromolecules, 8, 3365-3374.
202. Yang, C., Li, H., Goh, S.H., Li, J. (2007). Cationic star polymers consisting of a-cyclodextrin core and oligoethylenimine arms as nonviral gene delivery vectors. Biomaterials, 28, 3245-3254.
203. Menuel, S., Fontanay, S., Clarot, I., Duval, R.E., Diez, L., Marsura, A. (2008). Synthesis and complexation ability of a novel bis-(guanidinium)-tetrakis-(b-cyclodextrin) dendrimeric tetrapod as a potential gene delivery (DNA and siRNA) system. Study of cellular siRNA transfection. Bioconjugate Chem., 19, 2357-2362.
204. Li, J., Loh, X.J. (2008). Cyclodextrin-based supramolecular architectures: syntheses, structures, and applications for drug and gene delivery. Adv. Drug Deliv. Rev., 60, 1000-1017.
205. Tang, G.P., Guo, H.Y., Alexis, F., Wang, X., Zeng, S., Lim, T.M., Ding, J., Yang, Y.Y., Wang, S. (2006). Low molecular weight polyethylenimines linked by b-cyclodextrin for gene transfer into the nervous system. J. Gene Med., 8, 736-744.
206. Huang, H., Tang, G.,Wang, Q., Li, D., Shen, F., Zhou, J., Yu, H. (2006). Two novel non-viral gene delivery vectors: low molecular weight polyethylenimine cross-linked by (2-hydroxypropyl)-b-cyclodextrin or (2-hydroxypropyl)-c-cyclodextrin. Chem. Commun., Issue 22, 2382-2384.
207. Heidel, J.D. (2006). Linear cyclodextrin-containing polymers and their use as delivery agents. Expert Opin. Drug Deliv., 3, 641-646.
208. Shuai, X., Merdan, T., Unger, F., Kissel, T. (2005). Supramolecular gene delivery vectors showing enhanced transgene expression and good biocompatibility. Bioconjugate Chem., 16, 322-329.
209. Pun, S.H., Bellocq, N.C., Liu, A., Jensen, G., Machemer, T., Quijano, E., Schluep, T.,Wen, S., Engler, H., Heidel, J., Davis, M.E. (2004). Cyclodextrin-modified polyethylenimine polymers for gene delivery. Bioconjugate Chem., 15, 831-840.
210. Reineke, T.M., Davis, M.E. (2003). Structural effects of carbohydrate-containing polycations on gene delivery. 1. Carbohydrate size and its distance from charge centers. Bioconjugate Chem., 14, 247-254.
211. Popielarski, S.R., Mishra, S., Davis, M.E. (2003). Structural effects of carbohydrate-containing polycations on gene delivery: 3. Cyclodextrin type and functionalization. Bioconjugate Chem., 14, 672-678.
212. Heidel, J.D.,Yu, Z., Liu, J.Y., Rele, S.M., Liang,Y., Zeidan, R. K., Kornbrust, D.J., Davis, M.E. (2007). Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. Proc. Natl. Acad. Sci. USA, 104, 5715-5721.
213. Bartlett, D.W., Davis, M.E. (2007). Physicochemical and biological characterization of targeted, nucleic acid-containing nanoparticles. Bioconjugate Chem., 18, 456-468.
214. Quaglia, F., Ostacolo, L., Mazzaglia, A., Villari, V., Zaccaria, D., Sciortino, M.T. (2009). The intracellular effects of nonionic amphiphilic cyclodextrin nanoparticles in the delivery of anticancer drugs. Biomaterials, 30, 374-382.
215. Memisoglu-Bilensoy, E., Vural, I., Bochot, A., Renoir, J.M., Duchêne, D., Hincal, A.A. (2005). Tamoxifen citrate loaded amphiphilic b-cyclodextrin nanoparticles: in vitro characterization and cytotoxicity. J. Control. Release, 104, 489-496.
216. Memisoglu-Bilensoy, E., Dogan, A.L., Hincal, A.A. (2006). Cytotoxic evaluation of injectable cyclodextrin nanoparticles. J. Pharm. Pharmacol., 58, 585-589.
217. Bilensoy, E., Gurkaynak, O., Dogan, A.L., Hincal, A.A. (2008). Safety and efficacy of amphiphilic b-cyclodextrin nanoparticles for paclitaxel delivery. Int. J. Pharm., 347, 163-170.
218. Arima, H., Hagiwara, Y., Hirayama, F., Uekama, K. (2006). Enhancement of antitumor effect of doxorubicin by its complexation with c-cyclodextrin in pegylated liposomes. J. Drug Target., 14, 225-232.
219. Wada, K., Arima, H., Tsutsumi, T., Chihara, Y., Hattori, K., Hirayama, F., Uekama, K. (2005). Improvement of gene delivery mediated by mannosylated dendrimer/a-cyclodextrin conjugates. J. Control. Release, 104, 397-413.
220. Hwang, S.J., Bellocq, N.C., Davis, M.E. (2001). Effects of structure of b-cyclodextrin-containing polymers on gene delivery. Bioconjugate Chem., 12, 280-290.
221. Geze, A., Chau, L.T., Choisnard, L., Mathieu, J.P., Marti-Batlle, D., Riou, L., Putaux, J.L., Wouessidjewe, D. (2007). Biodistribution of intravenously administered amphiphilic b-cyclodextrin nanospheres. Int. J. Pharm., 344, 135-142.
222. Harada, A., Takashima, Y., Yamaguchi, H. (2009). Cyclodextrin-based supramolecular polymers. Chem. Soc. Rev., 38, 875-882.
223. Higashi, T., Hirayama, F., Yamashita, S., Misumi, S., Arima, H., Uekama, K. (2009). Slow-release system of pegylated lysozyme utilizing formation of polypseudorotaxanes with cyclodextrins. Int. J. Pharm., 374, 26-32.
224. Higashi, T., Hirayama, F., Misumi, S., Motoyama, K., Arima, H., Uekama, K. (2009). Polypseudorotaxane formation of randomly-pegylated insulin with cyclodextrins: slow release and resistance to enzymatic degradation. Chem. Pharm. Bull., 57, 541-544.